Table 3. Competing risk regression model to evaluate the effect of selected covariates on the risk of recurrence among patients with glottic laryngeal squamous cell carcinoma during 10 years' follow-up (n = 1127; 243 recurrences and 425 deaths).

SHR, sub-distribution hazard ratios; CI, confidence interval.

	Univariate analysis		Multivariate analysis
	SHR (95% CI)	P value	SHR (95% CI)	P value
Sex
Male	1		1
Female	0.67 (0.40–1.11)	0.12	0.66 (0.39–1.13)	0.13
Age (years)
0–59	1		1
60–69	0.79 (0.59–1.07)	0.12	0.83 (0.61–1.12)	0.23
70+	0.57 (0.42–0.79)	<0.01	0.62 (0.45–0.85)	<0.01
T-status
T1a	1		1
T1b	3.46 (1.99–6.01)	<0.001	3.93 (2.14–7.21)	<0.001
T2	3.52 (2.54–4.88)	<0.001	4.04 (2.65–6.17)	<0.001
T3	4.39 (3.03–6.37)	<0.001	5.79 (3.55–9.44)	<0.001
T4	1.88 (1.21–2.93)	<0.01	2.67 (1.39–5.12)	<0.01
N-status
N0	1		1
N1	1.12 (0.56–2.24)	0.74	0.90 (0.43–1.87)	0.77
N2+	1.65 (0.96–2.85)	0.07	1.52 (0.85–2.72)	0.16
Stage I-IV
I	1
II	3.06 (2.25–4.18)	<0.001
III	3.54 (2.46–5.10)	<0.001
IV	1.81 (1.22–2.69)	<0.01
Treatment modality
Radiotherapy	1		1
Transoral lasermicrosurgery	0.43 (0.30–0.61)	<0.001	1.58 (0.93–2.71)	0.09
Total laryngectomy	0.85 (0.55–1.31)	0.46	0.79 (0.45–1.40)	0.43
Chemo-radiotherapy	2.14 (1.07–4.31)	0.03	1.92 (0.89–4.16)	0.10
Period of treatment
1983–1989	1		1
1990–1996	0.79 (0.56–1.11)	0.18	0.80 (0.57–1.15)	0.23
1997–2003	0.75 (0.53–1.04)	0.09	0.68 (0.47–1.00)	0.05
2004–2010	0.59 (0.41–0.85)	<0.01	0.50 (0.33–0.77)	<0.01